Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III TO-203 sublingual tablet in pediatric HDM-induced allergic rhinitis
jRCT2080222901Phase 3Completed
- Sponsor
- Torii Pharmaceutical
- Start
- Jun 2015
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR) comparing TO-203 10,000 JAU with Placebo (2 arms). Started Jun 2015; status: completed.
02
Drugs
House dust mite allergen extract
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on jRCT2080222901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222901.